/Companies

ADEPTRIX CORP

1 known investors

Find your way into ADEPTRIX CORP

Adeptrix develops the exoBAMS platform, using antibody-based immunoaffinity capture of extracellular vesicles combined with MALDI mass spectrometry to profile proteins, lipids, metabolites and other molecules from a single blood sample. It provides custom assay development and bioanalytical services to researchers for biomarker discovery, disease-signature analysis, and translational research in oncology, neurology, and other disease areas.

Founders & leadership

VB
Vladislav BergoFounder

Investors · 1

Non-dilutive funding · 6 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2022$2.5M
National Institutes of Health (NIH)National Institutes of HealthPhase II2022$1.3M
National Institutes of Health (NIH)National Institutes of HealthPhase II2016$1.5M
National Science FoundationPhase II2015$750K
National Science FoundationPhase I2013$150K
National Institutes of Health (NIH)National Institutes of HealthPhase I2012$698.1K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does ADEPTRIX CORP do?
Adeptrix develops the exoBAMS platform, using antibody-based immunoaffinity capture of extracellular vesicles combined with MALDI mass spectrometry to profile proteins, lipids, metabolites and other molecules from a single blood sample. It provides custom assay development and bioanalytical services to researchers for biomarker discovery, disease-signature analysis, and translational research in oncology, neurology, and other disease areas.
Who founded ADEPTRIX CORP?
ADEPTRIX CORP was founded by Vladislav Bergo.
Who are ADEPTRIX CORP's investors?
ADEPTRIX CORP's investors include Formation Venture Engineering.